COMMUNIQUÉS West-GlobeNewswire

SlimTide Official Website 2026: Launch Effective Weight Loss Formula for Healthy Digestion and Metabolism. Slim Tide capsules Highlights Ingredients, Supplement Facts.
30/07/2026
SlimTide introduces natural weight loss capsules formulated to support healthy digestion and metabolism with plant-based ingredients. Learn about the formula, key ingredients, daily use, manufacturing information, [...]
Mdxhealth to Release Second Quarter 2026 Financial Results on August 13
30/07/2026
Company to Host Conference Call with Live Q&A, August 13, 2026, at 4:30pm ET / 22:30 CET IRVINE, California – July 30, 2026 ( GlobeNewswire ) – Mdxhealth SA (NASDAQ: MDXH), a leading precision diagnostics company, [...]
Correction: Inventiva annonce ses résultats financiers préliminaires pour le premier semestre 2026¹
30/07/2026
Trésorerie et équivalents de trésorerie de 166,1 millions d'euros et 67,8 millions d'euros de dépôts à court terme 2 au 30 juin 2026 Daix (France), New York City (New York, États-Unis), le 30 juillet, 2026 – Mise à jour [...]
Correction: Inventiva Announces Preliminary Financial Results for the First Half of 2026¹
30/07/2026
Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits 2 as at June 30, 2026 Daix (France), New York City (New York, United States), July 30, 2026 – Update to Press Release Dated July 29, [...]
InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing
30/07/2026
Ms. Kennedy returns to InspireMD having previously served as Sales Director supporting the initial U.S. launch of CGuard Prime MIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the [...]
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
30/07/2026
Expands Financial Capacity as Vonaprument and Tanruprubart Programs Advance Toward Registration BRISBANE, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the [...]
Alignment Healthcare Reports Second Quarter 2026 Results, Surpassing High End of Guidance Across All Key Metrics
30/07/2026
Generates $1.3 billion in total revenue, representing 31.6% growth year-over-year Grows Medicare Advantage membership 31.5% year-over-year to approximately 294,100 members Raises the midpoint of all full-year guidance [...]
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026
30/07/2026
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical [...]
Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda
30/07/2026
LEXINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a [...]
Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
30/07/2026
BOSTON, July 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it [...]
Xenon to Report Q2 2026 Financial Results on August 6, 2026
30/07/2026
VANCOUVER, BC and BOSTON, MA, July 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and [...]
CapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026
30/07/2026
SARATOGA, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced [...]
Abivax annonce un retour positif de la FDA à l’issue de ses échanges pré-NDA concernant l’obéfazimod
30/07/2026
Abivax annonce un retour positif de la FDA à l’issue de ses échanges pré-NDA concernant l’obéfazimod La Société confirme être en bonne voie pour déposer, d’ici la fin de l’année 2026, sa première demande d’autorisation [...]
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
30/07/2026
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative [...]
Merit Medical Reports Second Quarter 2026 Results And Updates Full-Year 2026 Guidance
30/07/2026
Financial Highlights† Reported revenue of $418.8 million, up 10% Constant currency revenue* and constant currency revenue, organic* up 9% and up 9%, respectively GAAP operating margin of 14.4%, compared to 12.3% in [...]
Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
30/07/2026
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., July 30, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the [...]
Stryker reports second quarter 2026 operating results
30/07/2026
Portage, Michigan, July 30, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the second quarter of 2026: Second Quarter Results Reported net sales increased 9.4% to $6.6 billion Organic net [...]
Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026
30/07/2026
CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living [...]
Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability
30/07/2026
Highl ights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is engaging payers and [...]

Pages